Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

DYN Dyne Therapeutics Inc

15,68

0,00 (0,00%)

06 Feb 2025 - Chiuso

Dati in Delay di 15 minuti

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Carlo Incerti

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Grafico Azioni Dyne Therapeutics (NASDAQ:DYN)
Storico
Da Gen 2025 a Feb 2025

Clicca qui per i Grafici di Dyne Therapeutics

Grafico Azioni Dyne Therapeutics (NASDAQ:DYN)
Storico
Da Feb 2024 a Feb 2025

Clicca qui per i Grafici di Dyne Therapeutics

Notizie Dyne Therapeutics Inc - DYN

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Lunedì 3 Febbraio 2025 (3 giorni fa) • GlobeNewswire Inc.

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
Martedì 21 Gennaio 2025 (2 settimane fa) • GlobeNewswire Inc.

Form 8-K - Current report
Venerdì 10 Gennaio 2025 (4 settimane fa) • Edgar (US Regulatory)

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101
Venerdì 10 Gennaio 2025 (4 settimane fa) • GlobeNewswire Inc.

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Giovedì 9 Gennaio 2025 (4 settimane fa) • GlobeNewswire Inc.

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Mercoledì 8 Gennaio 2025 (4 settimane fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Giovedì 12 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mercoledì 11 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martedì 10 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 6 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 6 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Venerdì 6 Dicembre 2024 (2 mesi fa) • Edgar (US Regulatory)

Più Dyne Therapeutics Inc Articoli Notizie

Marvell Technology

Agilent Technologies

American Airlines

Anheuser Busch InBev SA NV

Credit Agricole

ACS Actividades de Const...

Koninklijke Ahold Delhai...

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea